跳至主要内容
临床试验/NCT02728193
NCT02728193已完成不适用

The Research on Standard Treatments of Very-early Stage Hepatocellular Carcinoma: a Randomized Clinical Trial

Eastern Hepatobiliary Surgery Hospital1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
1
主要终点
Death

研究概览

简要总结

The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma
  • Tumor diameter<2cm
  • Child-Pugh class A liver function
  • Without major organ dysfunction
  • male or female patients > 18 years and <=70 years of age
  • Voluntary participation in this clinical trial

排除标准

  • Other anticancer treatment before therapy
  • Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer
  • Patients with other diseases that may affect the treatment of this treatment
  • History of other malignant tumors
  • Patients who are participating in other clinical trials
  • Pregnant, lactating women

结局指标

主要结局

Death

时间窗: 3 years

Recurrence

时间窗: 3 years

Hepatocellular Carcinoma will recurrence in 3 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ShenFeng

vice president of the Eastern Hepatobiliary Surgery Hospotal

Eastern Hepatobiliary Surgery Hospital

研究点 (1)

Loading locations...

相似试验